Abstract 1802MO
Background
Preoperative chemoradiotherapy (CRT) may increase antitumor immunity through enhancing T-cell activation and tumor infiltration. These effects could possibly sensitize tumours to immunotherapies, including checkpoint inhibitors. We explored whether preoperative CRT for locally advanced rectal cancer (LARC) induces immunologic changes and if the post-operative biological parameters are associated with tumour regression grade (TRG sec. Ryan –AJCC Eight ed.).
Methods
The multicenter randomized STAR-01 study compared a standard preoperative CRT regimen (50.4 Gy in 28 daily fractions with concomitant infused fluorouracil at the dose of 225 mg/m2/d) with the same regimen plus oxaliplatin given weekly at the dose of 60 mg/m2 in patients with LARC. Paired pre- and post-operative specimens were available for 81 patients and were analyzed by immunohistochemistry. The immunoistochemical analysis was performed with a panel of immune cells and associated factors as CD3, CD20, CD4/CD8, PD1. The pattern of tumor infiltrating lymphocytes (TILs) and related infiltrating lymphocytes (RILs) was also evaluated. Response to pre-operative chemoradiotherapy was assessed according to TRG.
Results
After therapy we observed a decreased CD4/CD8 ratio (p <0.001) and reduced expression level of CD20 (p<0.001). The expression level of CD3+ and PD-1+ cells after therapy did not change significantly. The relative increase of lymphocytes CD8+ inside CD4/CD8 ratio evaluated on post-operative samples was significantly associated with TRG 0 (p<0.001).
Conclusions
Our data suggest that CRT may induce an enrichment of CD8+ T lymphocytes and this translates in better response to CRT. The new frontier of best treatment could be the use of specific immune cells (T lymphocytes) to trigger the system's immune response against disease.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
University Hospital of Parma.
Funding
SNUPI ONLUS.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4MO - Preclinical evaluation of novel CDK4/6 inhibitor GLR2007 in breast and lung cancer models
Presenter: Lei Yin
Session: Mini oral session - Basic science
Resources:
Abstract
Slides
Webcast
5MO - CDK4/6 blockade is as effective as immune-checkpoint inhibition in tumor growth control of Mlh1-/- and Msh2loxP/loxP villin-Cre mice
Presenter: Inken Salewski
Session: Mini oral session - Basic science
Resources:
Abstract
Slides
Webcast
6MO - PCSK9 inhibitor evolocumab reduces cardiotoxicity and inflammation induced by doxorubicin-trastuzumab sequential treatment through MyD88/NF-kB/mTORC1 pathways
Presenter: Vincenzo Quagliariello
Session: Mini oral session - Basic science
Resources:
Abstract
Slides
Webcast
7MO - Effect of anti-CTLA-4 immunotherapy on lymphocyte subset and activation profiles and clonal composition on the B16F0 mouse melanoma model
Presenter: Diana Yuzhakova
Session: Mini oral session - Basic science
Resources:
Abstract
Slides
Webcast
1801MO - Neutrophils are associated with resistance to anti-PD-1 monotherapy in mismatch repair-deficient tumors
Presenter: Laetitia Nebot
Session: Mini oral session - Basic science
Resources:
Abstract
Slides
Webcast
Discussion 4MO, 5MO and 6MO
Presenter: Ruth Plummer
Session: Mini oral session - Basic science
Resources:
Slides
Webcast
Discussion 7MO, 1801MO and 1802MO
Presenter: Christian Ottensmeier
Session: Mini oral session - Basic science
Resources:
Slides
Webcast